NCT07172412 2025-09-30
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
Clinical Trials
5 trialsNCT06900088 2025-03-28
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06573138 2024-08-27
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06573151 2024-08-27
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
Ruijin Hospital
Phase 2 Not yet recruiting